Hester Biosciences Ltd Consolidated Net Profit in Q3 FY25 up 184% Y-o-Y to Rs. 11.41 crore; EBITDA up 12% to Rs. 13.85 crore
· In 9M FY25 Net Profit up 85% Y-o-Y to Rs. 27.29 crore crore
· In 9M FY25 EBITDA up 15% Y-o-Y to Rs. 55.53 crore
30 January 2025: Hester Biosciences Limited, one of India’s leading animal health company, manufacturing vaccines and health products has reported consolidated net profit of Rs. 11.41 crore in Q3FY25 ended December 2024 as against a net profit of Rs. 4.02 crore in Q3FY24, growth of 184%. Company reported revenue from operations of Rs. 63.22 crore for Q3FY25, fall of 6% Y-o-Y as compared to revenue from operations of Rs. 66.98 crore in Q3FY24. EBITDA during Q3FY25 ended December 2024 was reported at Rs. 13.85 crore, 12% growth Y-o-Y from Rs. 12.35 crore in Q3FY24. EPS for Q3FY25 was reported at Rs. 13.41 per share.
Looking ahead, our focus remains on achieving bottom-line targets while driving growth across divisions. The upcoming launch of the Avian Influenza vaccine, scheduled for release this year, is expected to significantly enhance the performance of the Poultry Healthcare Division and create new export opportunities. Additionally, we continue to prioritise the expansion of the Petcare Division, leveraging its strong growth momentum to solidify our market position.
9M FY25 Results
Company has reported net profit of Rs. 27.29 crore in 9M FY25 ended December 2024 as against net profit of Rs. 14.77 crore in 9M FY24, growth of 85%. Company reported revenue from operations of Rs. 229.18 crore for the 9M FY25, growth of 2% Y-o-Y. EBITDA during 9MFY25 ended December 2024 was reported at Rs. 55.53 crore, 15% growth Y-o-Y from Rs. 48.35 crore in 9M FY24. EPS for 9MFY25 was reported at Rs. 32.07 per share.
Disclaimer
The information provided in this media release is based on current facts and circumstances as of the date of publication. It may contain forward-looking statements, including but not limited to projections, expectations, or assumptions about future events or performance. These forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated. Hester Biosciences Ltd does not undertake any obligation to update, revise, or correct any forward-looking statements based on new information or future events. This release is intended for informational purposes only and does not constitute financial, investment, or professional advice.